The proposal could affect telehealth services that rely on outside facilities to produce the knockoff drugs in bulk.
FDA moves to remove semaglutide, tirzepatide, and liraglutide from its 503B compounding list, saying there's no shortage of ...
I keep buying Coca-Cola (NYSE:KO) and am not embarrassed about it. Every paycheck, every dividend reinvestment, every stock ...
The surge in GLP-1 compounding began a few years ago when high demand triggered widespread shortages. Shortages of ...
Shares of Microsoft (NASDAQ:MSFT | MSFT Price Prediction) are down 5% in midday trading Thursday, changing hands near $402 ...
Eli Lilly alleged that Empower lured customers away from their brand-name GLP-1 products and toward the pharmacy's ...
The U.S. Food and Drug Administration on Thursday proposed excluding Novo Nordisk and Eli Lilly's weight-loss drugs from a ...
FDA seeks restrict compounding of GLP-1 drugs by excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list to limit unauthorized use.
New full-stack offering turns content operations into an agentic growth engine NEW YORK and MUMBAI, India, April 30, 2026 /PRNewswire/ -- Firstsource Solutions Limited (NSE: FSL) (BSE: 532809), ...
Novo Nordisk (NVO) stock surged over 6% after FDA proposed removing weight-loss drugs from compounding list, hitting highest ...
Northrop Grumman was hit by some April showers, but it remains a compelling idea for investors looking for long-term growth ...
The FDA has proposed excluding certain active ingredients used in weight-loss drugs from Novo Nordisk and Eli Lilly on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results